Pharmaceutical

Bayer looks to expand Kerendia label to include heart failure

Bayer adds three new Phase III heart failure studies to the Kidney and type 2 diabetes drug, Kerendia, clinical development programme.

Sep 1, 2023 - 20:00
Bayer looks to expand Kerendia label to include heart failure
Bayer adds three new Phase III heart failure studies to the Kidney and type 2 diabetes drug, Kerendia, clinical development programme.
Read the original article

Tags:

Previous Article

NexImmune to lay off over half of its employees

Next Article

Signal: Novo Nordisk market cap higher than Danish GDP due to obesity drugs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MYK-224 by Bristol-Myers Squibb for Diastolic Heart Fai...

Feb 16, 2024

STAT+: Pharmalittle: Lilly drug shows biggest weight loss yet in mid-stage trial; Biogen shareholders elect director’s romantic partner to the board

STAT+: Pharmalittle: Lilly drug shows biggest weight lo...

Jun 28, 2023

Opinion: Four communication lessons we learned the hard way during the pandemic

Opinion: Four communication lessons we learned the hard...

Jun 6, 2023